Effect of Patisiran on Stroke Volume in Hereditary Transthyretin-Mediated Amyloidosis: Insights from Pressure–Volume Analysis of the APOLLO Study
European Journal of Heart Failure · 2023
DOI: 10.1002/ejhf.2783 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Hannah R Rosenblum und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center-NYP Hospital, New York, NY, USA. Hauptthemen laut MEDLINE: Heart Failure, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NHLBI NIH HHS, New York Academy of Medicine.
Themen: Schlaganfall
Abstract (Originalsprache)
Aims
Transthyretin-mediated (ATTR) amyloidosis is caused by deposition of transthyretin protein fibrils in the heart, nerves, and other organs. Patisiran, an RNA interference therapeutic that inhibits hepatic synthesis of transthyretin, was approved for the treatment of hereditary ATTR amyloidosis with polyneuropathy based on the phase 3 APOLLO study. We use left ventricular (LV) stroke volume (SV) to quantify LV function overtime and non-invasive pressure–volume techniques to delineate the effects of patisiran on LV mechanics in the pre-specified cardiac subpopulation of the APOLLO study. Methods and results Left ventricular SV was assessed by transthoracic echocardiography at baseline, and after 9 and 18 months of therapy. To determine the mechanisms underlying changes in LV SV, non-invasive pressure–volume parameters, including the end-systolic and end-diastolic pressure–volume relationship, were derived using single beat techniques. At baseline, the mean SV was 51 ± 14 ml. At 9 months, the least-squares mean change in SV was −0.3 ± 1.2 ml for patisiran and −5.4 ± 1.9 ml for placebo (p = 0.021). At 18 months, the least-squares mean change in SV was −1.7 ± 1.3 ml for patisiran and − 8.1 ± 2.3 ml for placebo (p = 0.016). Decline in LV SV was driven by diminished LV capacitance in placebo relative to patisiran.
Conclusions
Patisiran may delay progression of LV chamber dysfunction starting at 9 months of therapy. These data elucidate the mechanisms by which transthyretin-reducing therapies modulate progression of cardiac disease and need to be confirmed in ongoing phase 3 trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center-NYP Hospital, New York, NY, USA.
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Alnylam Pharmaceuticals, Cambridge, MA, USA.
- Cardiovascular Research Foundation, New York, NY, USA.
ORCID-Profile: Hannah R Rosenblum
Förderung
- NIA NIH HHS
- NHLBI NIH HHS
- New York Academy of Medicine
- NHLBI Division of Intramural Research
Zitieren
APA
Rosenblum, H. R., Griffin, J. M., Minamisawa, M., Prasad, N., Vest, J., White, M. T., Solomon, S. D., Burkhoff, D., & Maurer, M. S. (2023). Effect of Patisiran on Stroke Volume in Hereditary Transthyretin-Mediated Amyloidosis: Insights from Pressure–Volume Analysis of the APOLLO Study. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2783
Vancouver
Rosenblum HR, Griffin JM, Minamisawa M, Prasad N, Vest J, White MT, et al. Effect of Patisiran on Stroke Volume in Hereditary Transthyretin-Mediated Amyloidosis: Insights from Pressure–Volume Analysis of the APOLLO Study. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2783
BibTeX
@article{Rosenblum2023,
author = {Rosenblum, Hannah R and Griffin, Jan M and Minamisawa, Masatoshi and Prasad, Narayana and Vest, John and White, Matthew T and Solomon, Scott D and Burkhoff, Daniel and Maurer, Mathew S},
title = {Effect of Patisiran on Stroke Volume in Hereditary Transthyretin-Mediated Amyloidosis: Insights from Pressure–Volume Analysis of the APOLLO Study},
journal = {European Journal of Heart Failure},
year = {2023},
doi = {10.1002/ejhf.2783}
}
EUVIMED